A leading role for interferon as a treatment target in Sjögren syndrome

Affiliations

¹ Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands.
² Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands. f.g.m.kroese@umcg.nl.

Comment

Gwenny M Verstappen et al. Nat Rev Rheumatol. 2023 Aug.

. 2023 Aug;19(8):468-469.

doi: 10.1038/s41584-023-00991-9.

¹ Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands.
² Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands. f.g.m.kroese@umcg.nl.

No abstract available

Comment on

Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach.
Felten R, Ye T, Schleiss C, Schwikowski B, Sibilia J, Monneaux F, Dumortier H, Jonsson R, Lessard C, Ng F, Takeuchi T, Mariette X, Gottenberg JE. Felten R, et al. Rheumatology (Oxford). 2023 Nov 2;62(11):3715-3723. doi: 10.1093/rheumatology/kead096. Rheumatology (Oxford). 2023. PMID: 36869684 Free PMC article.

1. Bodewes, I. L. A., Björk, A., Versnel, M. A. & Wahren-Herlenius, M. Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome. Rheumatology (Oxford) 60, 2561–2573 (2019). - DOI
1. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014). - DOI - PubMed - PMC
1. Felten, R. et al. Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/kead096 (2023). - DOI - PubMed
1. Verstappen, G. M., Pringle, S., Bootsma, H. & Kroese, F. G. M. Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol. 17, 333–348 (2021). - DOI - PubMed - PMC
1. Juarez, M. et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome. Rheumatology (Oxford) 60, 1364–1375 (2021). - DOI - PubMed